Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > FreeStyle Libre system now compatible with smart insulin pens
People who use this flash glucose monitoring system along with multiple daily injections can now view their glucose and insulin data together in the FreeStyle LibreLink app. The smartphone app can now record people’s insulin dosage history and show the time and the amount of insulin taken alongside their glucose levels.
With around 65% of people with type 1 diabetes in the UK using Libre monitors, this could benefit a considerable number of the type 1 community.
The FreeStyle Libre 2 Sensor is a monitor that measures your blood glucose levels continuously. Users can see their current and recent blood glucose levels by scanning their phone over the device. The data is visible on the Freestyle LibreLink app on their phone to show much glucose is in their blood and whether this level is rising, dropping, or stable.
Novo Nordisk’s smart insulin pens are devices to inject insulin that record the dose and time of insulin injections. The Freestyle LibreLink smartphone app can now communicate with both the Libre 2 and these smart pens to store information from both devices. This will allow users to easily view their glucose levels and insulin dosing data together.
This could help lift some of the mental burden that comes with managing type 1 diabetes. It will help people understand how factors like medication, food and physical activity are affecting their glucose levels. This functionality can help people with type 1 take the right amount of insulin to keep their blood glucose levels more stable.
Neil Harris, General Manager of Abbott’s diabetes care business in the UK and Ireland, said: “Access to diabetes data empowers people by removing some of the guess-work related to the relentless management of the condition.”
Users of this integrated system also have the option to share this detailed data with their healthcare team through the cloud-based data system, LibreView. This would enable healthcare professionals to be more informed about an individual’s condition to help personalise their care.
Professor Partha S. Kar, OBE – who is national specialty advisor, diabetes at NHS England and consultant endocrinologist at Portsmouth Hospitals NHS Trust – was involved in the pilot of the partnership. He said: “It’s wonderful to see FreeStyle Libre integrating with key insulin delivery data from the NovoPen devices. This could be a really positive step in helping to make day-to-day management easier for people with diabetes and their healthcare teams. The evidence is undeniable of the benefits broader access to tech can bring for people with diabetes, so I am pleased to see this connectivity now available in the UK.”
Neil Harris added: “Abbott is continuing to pave the way for the future of diabetes care, not only through continuous innovation of the FreeStyle Libre systems, but also by working with Novo Nordisk and other insulin device companies to help further remove some of the daily burden for people with diabetes.”
The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.
As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.
Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.